Overview

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Indiana University

Collaborator:

Lupin Pharmaceuticals, Inc.

Treatments:

Secnidazole